China Jo-Jo Drugstores Granted Second Extension by Nasdaq to Meet Listing Requirements
December 16, 2023
☀️Trending News
China ($NASDAQ:CJJD) Jo-Jo Drugstores has been granted a second extension by the Nasdaq in order to satisfy its ongoing listing requirements. China Jo-Jo Drugstores is a leading online pharmaceutical retailer in China that offers a variety of products, including over-the-counter drugs, several types of traditional Chinese medicine, health and nutritional supplements, medical devices, and other healthcare products. However, due to their progress in meeting the requirements, the Nasdaq granted them a second extension, allowing them more time to fully satisfy the requirements. China Jo-Jo Drugstores has been working diligently to meet the Nasdaq’s listing requirements and is confident that they will be able to do so within the new timeline given. This will allow them to remain listed on the Nasdaq and maintain their status as a publicly traded company.
Price History
This news was welcomed by the company’s stock holders, as the stock opened at $0.2 and closed at $0.2, a 9.3% rise from the prior closing price of $0.2. This news was a sign of increasing investor confidence in the company, and it is expected that the company will be able to meet the listing requirements in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for CJJD. More…
| Total Revenues | Net Income | Net Margin |
| 148.81 | -21.14 | -13.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for CJJD. More…
| Operations | Investing | Financing |
| -3.28 | -0.32 | 2.37 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for CJJD. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 90.97 | 74.3 | 0.97 |
Key Ratios Snapshot
Some of the financial key ratios for CJJD are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.2% | -45.4% | -13.9% |
| FCF Margin | ROE | ROA |
| -2.4% | -62.6% | -14.2% |
Analysis
GoodWhale has analyzed the financials of CHINA JO-JO DRUGSTORES and, based on our Star Chart, determined that it has a low health score of 2/10. This suggests that the company is less likely to sustain future operations in times of crisis due to its cashflows and debt. It is strong in certain areas, such as asset management, but is weak in others, such as dividend payments and profitability. Additionally, we classify this company as an ‘elephant’, meaning that it is rich in assets after subtracting off liabilities. Investors who are interested in long-term investments with relatively low risk may find CHINA JO-JO DRUGSTORES attractive. More…
Peers
The competition between China Jo-Jo Drugstores Inc and its competitors, Anhui Huaren Health Pharmaceutical Co Ltd, 111 Inc, and Rite Aid Corp, is highly competitive. All four companies strive to provide top-notch quality products and services while also competing on convenience, price, and other factors. Each is determined to gain an edge on the other to become the leading drugstore in the market.
– Anhui Huaren Health Pharmaceutical Co Ltd ($SZSE:301408)
Anhui Huaren Health Pharmaceutical Co Ltd is a Chinese pharmaceutical company founded in 2003. The company specializes in the research, development, and production of traditional Chinese medicine and chemical drug products. As of 2023, the company has a market cap of 7.69B, indicating its relatively large presence in the industry. Additionally, its Return on Equity (ROE) of 15.65% shows its strong financial performance and ability to generate returns for its shareholders.
– 111 Inc ($NASDAQ:YI)
111 Inc is a leading Chinese healthcare provider and e-commerce platform. The company provides a wide range of services ranging from pharmacy retailing, drug discovery and development, medical services, and digital healthcare solutions. As of 2023, the company has a market capitalization of 228.06 million USD and an impressive return on equity of 57.73%. This indicates that the company has been able to generate significant profits from its investments, which makes it attractive to potential investors. Furthermore, 111 Inc’s diversified business model and competitive services have enabled them to remain competitive in the market and create significant value for their shareholders.
– Rite Aid Corp ($NYSE:RAD)
Rite Aid Corp is a retail pharmacy chain in the United States, operating more than 2,400 stores across the country. The company has a market capitalization of 142.44M as of 2023, which is the total market value of all of the company’s outstanding shares. Additionally, Rite Aid Corp boasts a high return on equity of 115.73%, which is indicative of the company’s ability to generate profits from its existing shareholders’ investments. This suggests that investors are satisfied with the performance of their investments in the company.
Summary
China Jo-Jo Drugstores recently received a second extension from Nasdaq to meet its continuing listing requirements. This gave investors confidence in the company’s potential prospects and the stock price surged the same day. Analysts are bullish about investing in this company due to its strong financial performance over the past few years, driven by a focus on expanding its distribution network and growing customer base. The company’s cost efficiency initiatives, such as optimizing inventory and streamlining operational processes, have also helped it to remain competitive in the market.
Additionally, it has been able to establish a strong presence in both online and offline channels. Overall, investors view China Jo-Jo Drugstores as a lucrative investment opportunity with solid potential for long-term growth.
Related Posts
Recent Posts
